Actinium Pharmaceuticals (ATNM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $4.00 price target.
Joseph Pantginis has given his Buy rating due to a combination of factors including Actinium Pharmaceuticals’ strategic advancements in their clinical programs. The company has initiated a new clinical trial program to evaluate the efficacy of Actimab-A in combination with Keytruda and Opdivo for treating head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). This trial aims to enhance the effectiveness of these checkpoint inhibitors by targeting CD33-expressing myeloid-derived suppressor cells (MDSCs), which have been a limiting factor in the efficacy of Keytruda and Opdivo.
Additionally, Actinium’s commencement of a Phase 1 trial combining Actimab-A with venetoclax and STX-727 for acute myeloid leukemia (AML) patients showcases its innovative approach to addressing unmet medical needs. The trial is supported by previous clinical data that demonstrated Actimab-A’s potential as a backbone combination therapy in AML. These developments, coupled with the potential cost savings from a Cooperative Research and Development Agreement with the National Cancer Institute, provide a strong foundation for Pantginis’s optimistic outlook on Actinium Pharmaceuticals.
In another report released on March 12, JonesTrading also maintained a Buy rating on the stock with a $9.00 price target.